TIM-3 – Galectin-9 Pathway


TIM-3 - Galectin-9 PathwayT cell immunoglobulin and mucin-3 (TIM-3; HAVcr-2) is an immune checkpoint receptor involved in the suppression of both innate and adaptive immune cells. It is expressed on a wide variety of immune cells, including cytotoxic T cells, regulatory T cells (Tregs), natural killer (NK) cells and antigen-presenting cells (APCs) such as dendritic cells (DCs). TIM-3 suppresses effector cells through the interaction with a broad array of ligands: carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), galectin-9, phosphatidylserine (PS) and high mobility group box 1 (HMGB1). Blockade of TIM-3 can rescue NK-cell activity, promotes tumor antigen processing and reinvigorates exhausted T cells, restoring their proliferation and function.


LIT:  Tim-3 and its role in regulating anti-tumor immunity: M. Das, et al.; Immunol. Rev. 276, 97 (2017) • TIM-3, a promising target for cancer immunotherapy: Y. He, et al.; Onco Targets Ther. 11, 7005 (2018)

 

 


Biologically Active TIM-3 and Galectin-9 Proteins  

Product Name PID Source Endotoxin Species
Galectin-9 (human):Fc (human) (rec.) CHI-HF-210GAL9 HEK 293 cells <0.005EU/µg Human
HMGB1 (human) (rec.) (His) CHI-HR-200HMGB1 E. coli <0.1EU/µg Human
HMGB1 (rat) (rec.) (His) CHI-RR-300HMGB1 E. coli <0.1EU/µg Rat
HMGB1 (rat):Fc (human) (rec.) CHI-RF-311HMGB1 CHO cells <0.06EU/µg Rat
Tim-3 (mouse):Fc (mouse) (rec.) CHI-MF-110T3 HEK 293 cells <0.005EU/µg Mouse
Tim-3 (mouse):Fc (human) (rec.) CHI-MF-111T3 CHO cells <0.06EU/µg Mouse
Tim-3 (human):Fc (human) (rec.) CHI-HF-210T3 CHO cells <0.06EU/µg Human
Tim-3 (human):Fc (mouse) (rec.) CHI-HF-211T3 CHO cells <0.06EU/µg Human

VALIDATED Antibodies for TIM-3 and Galectin-9 Research

 

Product Name PID Isotype Applications Species
Tim-3 (mouse), mAb (TI 142F) AG-20A-0030 Rat IgG2aκ ELISA, FACS Mouse
Tim-3 (human), mAb (AG-IHC003) AG-20B-6021 Mouse IgG1 IHC Human


Select Your Pathway of Interest  & Discover High Quality Reagents


© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.